New cancer vaccine shows promising results for certain patients
Researchers at Dana-Farber Cancer Institute, Harvard Medical School, Yale Cancer Center and other universities have announced early findings from a study of an anti-tumor vaccine for patients with advanced kidney cancer.
"Patients with stage 3 or 4 kidney cancer are at high risk of recurrence," said co-senior author and co-principal investigator Toni Choueiri, MD, director of the Lank Center for Genitourinary Cancer at Dana-Farber, in a press release.
"The tools we have to lower that risk are not perfect, and we are relentlessly looking for more."
After undergoing surgery to remove a malignant tumor, the study's nine participants received a cancer vaccine that was intended to "train" their immune systems to identify and attack any lingering cancer cells, according to the press release.
Each vaccine was personalized to match the individual patient's tumor type based on cancer cells that were removed during surgery. These cells contain "neoantigens," which are "tiny fragments of mutant proteins," the release stated. The researchers used "predictive algorithms" to determine which neoantigens should be included in the vaccine to provide the highest level of immunity.
Five of the patients also received ipilimumab, a type of immunotherapy drug.
All nine patients showed a "successful anti-cancer immune response" after getting the vaccine. After an average of 34.7 months, they all remained cancer-free.
Within three weeks of receiving the vaccine, patients showed an "immune response," with T-cells spiking by more than 166 times, the release said. (T-cells, also known as T lymphocytes, are immune cells that help to fight cancer and prevent infection.)
"The tools we have to lower that risk are not perfect and we are relentlessly looking for more."
In the study, the T cells were found to remain in the patient's body for up to three years and attacked the existing tumor cells.
"We observed a rapid, substantial, and durable expansion of new T cell clones related to the vaccine," said Patrick Ott, MD, PhD, director of the Center for Cancer Vaccines at Dana-Farber.
"These results support the feasibility of creating a highly immunogenic personalized neoantigen vaccine in a lower mutation burden tumor and are encouraging, though larger-scale studies will be required to fully understand the clinical efficacy of this approach."
The results of the clinical trial were reported in the journal Nature on Feb. 5.
"We're very excited about these results, which show such a positive response in all nine patients with kidney cancer," Choueiri noted.
For most stage 3 or 4 kidney cancer patients, the standard treatment is surgical removal of the tumor, which is often followed by an immunotherapy drug called Pembrolizumab (Keytruda).
"Pembrolizumab induces an immune response that reduces the risk of the cancer coming back," according to Dana-Farber. "However, about two-thirds of patients can still recur and have limited treatment options."
First author David A. Braun, MD, PhD, a medical oncologist and physician-scientist at Yale Cancer Center and Yale School of Medicine, noted that the approach used in this study was "truly distinct from vaccine attempts in kidney cancer."
"We pick targets that are unique to the cancer and different from any normal part of the body, so the immune system can be effectively 'steered' toward the cancer in a very specific way," Braun said in the release.
"We learned which specific targets in the cancer are most susceptible to immune attack and demonstrated that this approach can generate long-lasting immune responses, directing the immune system to recognize cancer. We believe this work can form a foundation for the development of neoantigen vaccines in kidney cancer."
Charles Nguyen, MD, a medical oncologist who specializes in kidney cancer at City of Hope in Orange County, California, noted that kidney cancer is among the 10 most common cancers among men and women in the U.S.
"This is a very exciting and promising tool for many of our patients with kidney cancer, where we can one day make a cure possible for all."
"Patients with early stage (localized) kidney cancer are often first treated with surgery to remove the tumor — however, many patients have a risk of the cancer coming back years after surgery, and there is a great interest in finding ways to lower the risk of cancer recurrence," Nguyen, who was not involved in the study, told Fox News Digital.
"This exciting clinical trial evaluated a personalized cancer vaccine that uses genetic information from each patient's cancer to train and enhance the patient's immune system to recognize the cancer and prevent it from recurring."
While Nguyen acknowledged that this was a small study, all nine patients who received the vaccine were cancer-free even three years later.
"This is a very exciting and promising tool for many of our patients with kidney cancer, where we can one day make a cure possible for all."
Some patients did experience side effects from the vaccine, including local reactions at the vaccine injection site and flu-like symptoms, although "no higher-grade side effects were reported."
The researchers also acknowledged that there were some limitations associated with the study.
"There were limitations in the antigen-prediction tools available at the time and in the ability to target only a single antigen," they wrote.
"Moreover, it was conducted in the setting of active metastatic disease in a number of study participants."
Future research with larger clinical trials are planned to confirm the vaccine's effectiveness and full potential, the release stated.
For more Health articles, visit www.foxnews.com/health
Funding for this study was provided by the Gateway for Cancer Research, the U.S. Department of Defense, Yale Cancer Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Trust Family Foundation, Michael Brigham, Pan-Mass Challenge, Hinda L. and Arthur Marcus Foundation, The Loker Pinard Fund for Kidney Cancer Research at Dana-Farber Cancer Institute, National Institutes of Health, Conquer Cancer Foundation/Sontag Foundation, the release stated.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Leukemia Relapse: PD-1 Inhibition Shows Mixed Results
TOPLINE: Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapse after hematopoietic cell transplantation (HCT). Mixed CD3 chimerism predicted response, but 37.5% developed severe graft-vs-host disease (GVHD). METHODOLOGY: A prospective phase 1B clinical trial enrolled 16 patients with AML (n = 12) and MDS (n = 4) who experienced relapse after HCT, with a median time to relapse of 5.5 months and median pretreatment bone marrow blast percentage of 21.5%. Participants received 200 mg pembrolizumab intravenously every 21 days for up to four cycles (induction), with responding patients eligible for maintenance therapy up to 1 year. Primary objectives included assessment of safety, overall response rate to pembrolizumab with or without subsequent chemotherapy, and rates of GVHD or clinically significant immune-mediated toxicity. Response evaluation occurred through bone marrow examination on day 35 (after cycle 2) and day 77 (after cycle 4), with complete remission defined as bone marrow blasts less than 5% and absence of circulating blasts. TAKEAWAY: The overall response rate was 31.3%, consisting of three complete remissions (18.8%) and two partial remissions (13.5%), with a median response duration of 610 days. Patients with mixed CD3 chimerism showed significantly higher response rates compared to those with full donor chimerism (50% vs 0%; P = .03). Severe (grades 3-4) GVHD developed in 37.5% of patients, with most cases resistant to corticosteroids and contributing to death in 25% of participants. The 1-year overall survival was 37.5% and event-free survival was 31.3%, with AML patients showing 1-year overall survival of 50.0%. IN PRACTICE: 'PD-1 inhibition led to durable remission in on -third of the patients experiencing early relapse after HCT, suggesting that this approach may augment the GVL [graft-vs-leukemia] response. Responses were exclusively observed in the setting of mixed CD3 donor chimerism. Immune toxicities (GVHD) were a barrier to successful treatment outcome,' the authors of the study wrote. 'The results of the study highlight the challenge of attempting to dissect the graft-vs-leukemia effect from immunologic toxicity in patients with HCT,' Roman M. Shapiro and Robert J. Soiffer, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, said in a press release. SOURCE: The study was led by John M. Magenau, Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center in Ann Arbor, Michigan. It was published online on August 12 in Blood Advances. LIMITATIONS: According to the authors, the small sample size limited their ability to determine the extent to which pembrolizumab could separate graft-vs-leukemia effects from GVHD. The researchers note that, while some patients achieved response without GVHD, the limited cohort size may have confounded interpretation of significant variables, including response patterns in patients with high blast percentage, very early relapse, monosomal karyotype, or TP53 mutations. DISCLOSURES: Magenau declared receiving support through a National Institutes of Health career development award (K23AI123595) and a Rogel Cancer Center Scholarship. The study was supported by a research grant (54053) from the Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
a day ago
- Medscape
GVHD in Children: What Dermatologists Need to Know
SEATTLE — With increasing survival rates after allogeneic hematopoietic stem cell transplantation (HSCT) in children, dermatologists may be seeing more skin conditions associated with HSCT, including the cutaneous manifestations of graft-vs-host disease (GVHD), according to Jennifer T. Huang, MD, associate professor of dermatology and pediatrics, Harvard Medical School, Boston. GVHD is the most common complication following HSCT, and while it can affect any body organ, the skin is the most commonly involved. 'In the US, there are 85 centers in 37 states that perform pediatric allogeneic transplants,' Huang said at the Society for Pediatric Dermatology (SPD) 2025 Annual Meeting. In the US, about 1400 allogeneic transplants are performed each year, and 15% are in children, she noted. While HSCT is generally associated with cancer treatment, in about one third of cases in children, allogeneic HSCT is used to treat nonmalignant conditions such as bone marrow failure, primary immunodeficiency, and hemoglobinopathy. Currently, 5-year survival after pediatric allogeneic HSCT ranges from 50% to 90%, said Huang, who is also director of pediatric oncodermatology at Boston Children's Hospital, Boston. As a result, dermatologists may be seeing more cases of not only cutaneous manifestations of GVHD but also other HSCT-associated effects, such as persistent hair loss and skin cancer. The grading criteria for acute GVHD are well established for the skin, liver, and intestinal tract effects. For the skin, severity is staged based on the percentage of body surface area affected by a rash and the presence or absence of blistering. Generalized erythroderma and the presence of blisters indicate a more severe stage of GVHD. When it presents with symptoms such as generalized erythroderma, desquamation, and bullae, acute, severe GVHD can mimic toxic epidermal necrolysis (TEN), a severe drug-induced skin reaction characterized by widespread epidermal necrosis. Because transplant recipients often take many medications, it can be difficult to distinguish between the two conditions. TEN-like GVHD is rare, noted Huang, a co-author of a case series and literature review of TEN-like acute GVHD in pediatric bone marrow transplant patients. 'Of the 10 patients in the series with TEN-like GVHD, seven had other organ involvement, and 80% died,' she said. Managing Acute GVHD When managing a patient with acute GVHD with cutaneous manifestations, a biopsy may not be very helpful. She referred to a small study conducted at Boston Children's Hospital of 27 children who underwent a biopsy for skin eruptions suspicious for acute GVHD. The biopsy yielded a definitive diagnosis of GVHD or other disorder in only four (15%) cases and changed management in only two patients. In contrast, a dermatology consultation was associated with changes in clinical management in nearly 80% of the patients (21 of the 27) compared with 7.4% (2 of the 27) of skin biopsy results. 'We should be careful about doing biopsies in these patients, unless you think that there's another diagnosis that's a slam dunk histopathological diagnosis like leukemia cutis,' she said. 'Otherwise, you cannot differentiate GVHD from drug rash or viral exanthem, and you should rely on your clinical signs and symptoms.' Second, dermatologists need to know the details of the transplant to evaluate the risk, and third, 'look for acral involvement and systemic symptoms to lead you to the diagnosis, and don't rely on skin biopsy,' she said. 'Importantly, treat aggressively and early, especially if there is TEN-like GVHD.' Chronic GVHD Acute GVHD is the most important risk factor for developing chronic GVHD, a complex, multisystem disorder that is distinct from acute GVHD, with features that resemble autoimmune and other immunologic conditions. 'I think of chronic GVHD as alloimmunity,' Huang explained. Continuing inflammation activates an 'alloresponse,' resulting in the development of what appears to be an autoimmune disease affecting the skin and other organs 'as a response to chronic inflammation,' she said. Chronic skin GVHD most commonly presents in children with eczematous, sclerotic, or lichenoid skin changes and can often be diagnosed clinically without a biopsy in many cases. If a patient presents with diagnostic features such as poikiloderma, lichen planus-like features, sclerotic features, morphea-like features, and lichen sclerosus-like features, biopsy confirmation is generally not required, she noted. Regardless of whether it's acute or chronic, there are minimal histopathologic criteria for diagnosing active GVHD, Huang said. These include the presence of apoptosis in the epidermal basal layer or lower Malpighian layer or outer root sheath of hair follicles, or acrosyringium, lichenoid inflammation, vacuolar changes, and lymphocytic satellitosis. Management of chronic GVHD is usually multifactorial, with three main goals: to improve quality of life (addressing symptoms, daily activities, and visible changes); to minimize systemic immunosuppression; and to avoid permanent disfigurement. 'There are effective topical therapies for skin GVHD that can minimize systemic immunosuppression, and these can often do the trick,' which include steroids, as well as tacrolimus and ruxolitinib, she said. Preventive measures are underutilized, such as gentle care for dry skin, treating other rashes, and, very importantly, sun protection, because sunburn can trigger GVHD, she added. Phototherapy is also a good therapeutic option for skin-directed therapy. In addition, there are now several FDA-approved targeted therapies for chronic GVHD in children, including ibrutinib, ruxolitinib, belumosudil, and axatilimab. 'As dermatologists, we can also guide therapy with biologics that we feel comfortable with but that our other colleagues may not know much about,' said Huang. 'Let's maximize skin-directed therapies for treating this disease. We don't want to lose the graft, and we also don't want permanent disfigurement — this has a lot to do with recognizing the disease early and treating it aggressively.' Huang reported having no relevant financial relationships or conflicts of interest.
Yahoo
2 days ago
- Yahoo
IO Biotech sees path forward for skin cancer vaccine despite study setback
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. An experimental cancer vaccine fell short of its main objective in a Phase 3 trial in melanoma, causing shares of the shot's developer, IO Biotech, to fall by double digits on Monday. IO Biotech, however, still believes the vaccine performed well enough to warrant a potential approval consideration from U.S. regulators. The company noted how the study, which compared a regimen of its shot and Merck & Co.'s immunotherapy Keytruda to Keytruda alone, failed by the slimmest of margins. Executives also pointed to other analyses showing potentially stronger benefits among those who hadn't previously received drugs like Keytruda or aren't likely to respond to them. 'It was a very narrow miss, just by a hair,' said Mai-Britt Zocca, IO's CEO, on a Monday conference call with Wall Street analysts. Called Cylembio, IO's cancer vaccine consists of engineered peptides that are supposed to provoke an immune response to certain proteins expressed on tumor cells. Those proteins are two of the immune 'checkpoints,' PD-L1 and IDO1, long studied by drugmakers. Cylembio is designed as an 'off-the-shelf' vaccine, which would be simpler to produce than the 'personalized' shots being developed by Moderna, BioNTech and others. IO Biotech's trial enrolled more than 400 people whose newly diagnosed melanoma couldn't be surgically removed or had spread to other parts of the body. Study participants were randomized to receive Keytruda alone or Keytruda plus Cylembio. The company's primary objective was to prove the Cylembio-Keytruda combination could hold tumors in check longer than Keytruda alone. According to the company, people who got the vaccine-immunotherapy combination had a 23% lower relative risk of dying or their disease progressing than those who got Keytruda alone, which didn't meet the threshold of statistical significance. People who tested negative for a protein linked to immunotherapy responses had a 46% relative risk reduction, IO Biotech said. That analysis was part of IO's pre-specified statistical plan, indicating that regulators may view it more favorably. Yet another analysis of people who hadn't previously received Keytruda or other drugs like it wasn't part of that plan. IO Biotech's finding that those enrollees had a 26% relative risk reduction in disease progression or death is considered 'nominal,' then, meaning FDA reviewers would likely tread cautiously. IO executives said they will meet with the FDA in the third quarter to discuss the findings, and hope to seek approval by the end of the year. Investors appear skeptical of the company's chances, though. IO Biotech's stock price fell by more than 20% during Monday morning trading, adding more losses for a company that's lost most of its value since going public in 2021. Zocca said the company had closed the second quarter with $28 million in cash, providing it with enough to finance operations through the first quarter of 2026. The company needs positive study data as well as a successful FDA submission to unlock a 15 million euro, or $17.4 million, tranche of a loan it has secured from the European Investment Bank. Recommended Reading Lilly's new Alzheimer's data may both help and hinder rival Biogen Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
